Edward Feener, Chief Scientific Officer of KalVista Pharmaceuticals Inc (NASDAQ:KALV), executed a sale of 17,321 shares in the company on January 9, 2024, according to a recent SEC Filing.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 17,605 shares of the stock in a transaction dated Wednesday, January 3rd. The stock was acquired at an average cost of $12.20 per share, with a total value of $214,781.00. Following the completion of the transaction, the insider now owns […]
XORTX Therapeutics Inc (XRTX) Appoints Patrick Treanor to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.